Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics

PLoS One. 2013;8(1):e53466. doi: 10.1371/journal.pone.0053466. Epub 2013 Jan 9.

Abstract

Setting: Nationwide Canadian public health surveillance.

Objective: Description of demographic features and disease characteristics of drug-resistant tuberculosis (TB) in Canada over a 12 year period.

Design: Continuous surveillance of all cases of culture-confirmed TB in Canada. Demographic and microbiologic features were analyzed and comparisons between drug-susceptible, multidrug-resistant (MDR), and drug-resistant not-MDR were made. Cases of extensively drug resistant TB are described.

Results: 15,993 cases of culture-confirmed TB were reported during the study period. There were 5 cases of XDR-TB, 177 cases of MDR-TB, and 1,234 cases of first-line drug resistance not-MDR. The majority of drug-resistant cases were reported in foreign-born individuals, with drug-resistant cases diagnosed earlier post-arrival in Canada compared to drug-susceptible cases. In MDR-TB isolates, there was a high rate of drug-resistance to other first- and second-line drugs, making reliable empiric therapeutic recommendations for MDR-TB difficult. There was a statistically significant association between both MDR and drug-resistance not-MDR, and the risk of a negative treatment outcome (defined as treatment failure, absconded, or treatment ongoing >3 yrs).

Conclusion: Drug-resistance complicates TB management even in developed nations with well-established TB control programs. The predominantly international origin of drug-resistant cases highlights the need for global strategies to combat TB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use*
  • Canada / epidemiology
  • Child
  • Child, Preschool
  • Demography
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Extensively Drug-Resistant Tuberculosis / microbiology
  • Female
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / isolation & purification
  • Time Factors
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / epidemiology
  • Tuberculosis, Pulmonary / microbiology
  • World Health Organization
  • Young Adult

Substances

  • Antitubercular Agents

Grants and funding

In-kind support was provided by the Public Health Agency of Canada, Ottawa, Ontario; and the Tuberculosis Program Evaluation and Research Unit, Edmonton, Alberta. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.